Industry Newsneuralplexerstructure predictionsmall moleculestakeda
Iambic Partners With Takeda To Accelerate Drug Design
|
9.3
Iambic and Takeda Pharmaceutical on Monday announced a multi-year partnership worth more than $1.7 billion to use AI in designing small-molecule drugs for cancer and gastrointestinal diseases. Under the deal Iambic will receive upfront and milestone payments plus royalties, while Takeda gains access to Iambic's NeuralPLexer model to predict molecule–protein binding and shorten discovery timelines.
Scoring Rationale
Significant, well-sourced pharma–AI partnership with industry-wide implications; score limited by early-stage development details available.
Practice interview problems based on real data
1,500+ SQL & Python problems across 15 industry datasets — the exact type of data you work with.
Try 250 free problems
